ATRX and central nervous system cancer: To determine the extent to which ATRX-deficient glioma models remain sensitive to dsRNA immune agonism in the context of IDH1R132H, we subjected our isogenic CT2A lines to HMW poly(I:C), monitoring levels of key pathway constituents.